Me Today guidance upgrade for FY26
1
7 May 2026
Me Today guidance upgrade for FY26
• Me Today now expects gross revenue to exceed $7.4m for FY26, an
increase of 27% on FY25 and to exceed previous guidance by 14%
• Revenue growth from strong NZ market and a growing international
business
• New SE Asia Distribution Agreement
• EBITDA loss expected to be less than $1.6m, a reduction of 25% on
FY25
• Ongoing investment in product and brand
Me Today advises that it now expects gross revenue for the year ended 30 June 2026 to exceed
$7.4m, an increase of 27% on the year ended 30 June 2025 and an increase of 14% on the guidance
provided in February.
The expected increase in gross revenue comes from growth in the New Zealand market and strong
international opportunities.
New Zealand
Me Today continues to grow in the New Zealand market. The growth arises from expanded shelf
presence in our biggest retail partner together with the successful launch of new product.
A new planogram was launched during March, meaning the brand is now more visible in store. This
is supported by scan data with retail sales increasing 113% in the 12 months to 29 April 2026 on the
previous 12-month period in our largest NZ retail partner.
In FY26 the brand has heavily invested in new products with 15 products launched so far this
financial year. The new products include the launch of the Me Today Potent Herbal range of liquid
supplements and new supplements in varying formats across capsules, resin and a liquid spray for
stress support. In addition, we have further strengthened our women’s wellness portfolio with the
successful launch of five new functional powder blends. This is the first entry by Me Today into
great-tasting powdered supplements.
We are also developing further products in powders which we hope to launch into the New Zealand
market prior to 30 June.
SE Asia
As advised previously, Me Today has been working on an opportunity to launch the Me Today brand
in SE Asia. Those discussions have successfully concluded, and we have now signed a distribution
agreement for the brand in Singapore, Malaysia, Thailand and Vietnam. The agreement is an
exclusive arrangement with minimum sales targets over a five-year period. The distributor has an
established network in SE Asia, and we are excited about the growth opportunities for the brand
across these markets. The launch will occur firstly in Singapore. Next week the brand is hosting top
performing agents in New Zealand and then we travel to be part of a wider launch event in
Singapore in July. We have received an opening purchase order to support the launch relating to ten
products which the business is working to fulfill during May and June. The Singapore market is the
2
quickest from a regulatory perspective with Malaysia and the other markets following in the 2027
calendar year as the registration requirements complete.
Me Today China brand Licensing Agreement
The licence fee payable in respect to the Me Today China trademark by the licensor for the second
year of our partnership to 31 March 2026 has now been calculated. The fee payable to Me Today is
calculated as a percentage of sales of Me Today product in China. The licence fee payable for the 12
months ended 31 March 2026 is NZD $1.1m and the payment was received prior to 30 April.
As described previously the arrangement in China is an exciting opportunity for the Me Today brand.
Our partner has considerable scale in China and the success of the sales of the Me Today brand
through their network is now being realised through the licence fee revenue being earned by Me
Today in New Zealand.
In conjunction with our Chinese partner, we continue to develop new product, so the sales revenue
is now being generated from a wider range of products. Me Today product is also now being
promoted online wider than just the Chinese Tik Tok platform Douyin, which means the brand is
now reaching a broader consumer base in Mainland China.
Other Markets
The brand continues to have a presence in other international markets with ongoing sales activity in
the USA, Japan, Ireland and the UAE. In the USA we continue to build relationships in both offline
and online channels.
The offline business in the USA is Manuka honey focused with orders so far this financial year
totaling NZD $1.04m, with one open order to be delivered prior to 30 June. We have an ongoing
opportunity in this market subject to us securing Manuka honey at the right price, grade and
quantity.
EBITDA Guidance
The business continues to focus on growing revenue and reducing costs where possible,
acknowledging that investment is still required in the brand and the distribution network. Alongside
the revenue growth has seen growth in investment in products, people and brand. For the full FY26
financial year the business is now expecting operating EBITDA loss to be less than $1.6m, which is
$100k down on February guidance and a 25% reduction in the loss for the year ended 30 June 2025.
For further information, please contact:
Grant Baker
Chairman, Me Today Limited
021 729 800
Stephen Sinclair
CEO, Me Today Limited
021 330 053
stephen@metoday.com
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- CVT — Comvita Limited: CVT Delivers First-Half Priorities as Turnaround Continues2026-02-22
“Greater China: Challenging But On Track Progress: •Maintained #1 brand position with >50% market share. •Maintained #1 in online sales. •Locally-led innovation delivering results. Challenges: •Continued softer consumer demand. •Ongoing commoditisation of lower UMF grades. Focus…”
- ATM — The a2 Milk Company Limited: 1H26 Results and Interim Report2026-02-15
“Refer to Investor Day materials communicated to the market on 27 October 2021 for further information on medium-term ambition, strategy, risks and opportunities Medium-term revenue and EBITDA margin ambitionCommentaryAreas of planned revenue growth •Strong 1H26 result and upgrade…”
- AFT — AFT Pharmaceuticals Limited: AFT delivers double digit revenue growth and record earning2026-05-20
“Important Notice AFT PHARMACEUTICALS WORKING TO IMPROVE YOUR HEALTH2 This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of the performance of AFT. It is not prepared for any other purpose and must not be provided to any pe…”